On February 27th, the China Telecom Cloud and Connectivity Summit was successfully held at the grand 2024 Mobile World Congress (MWC2024) in Barcelona. With the theme of " Leading the...

Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) will be presented at the American Association for Cancer...

-- Data support ongoing development of antibody-drug conjugate (ADC) program targeting HER3-expressing cancers – -- On-track to nominate development candidate in 2024 -- BOSTON, March 5, 2024...

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that interim...

Preclinical data demonstrate presence of CD161 expressing T cells in anti-PD1 non-responder tumors and enhanced T cell mediated cytotoxicity with combination treatment of IMT-009 and anti-PD1,...

Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR-driven cancers, today announced poster...

Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage immunology company, today announced it will be providing updates on its RNA immunotherapies at multiple presentations at the American...

-Sapience to present data across its pipeline, including non-clinical immunotherapy results on ST316 and ST101 and preclinical results on its novel AP-1 complex antagonist TARRYTOWN, N.Y., March...

GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, announced today that its...

Celsius Holdings, Inc., (Nasdaq: CELH), maker of Celsius®, the premium lifestyle energy drink formulated to power active lifestyles with ESSENTIAL ENERGY™, today announced that the company will...